open access

Vol 77, No 5 (2009)
Invited review paper
Submitted: 2013-02-22
Published online: 2009-08-12
Get Citation

Smoking and lung cancer

Ewa Jassem, Amelia Szymanowska, Alicja Siemińska, Jacek Jassem
DOI: 10.5603/ARM.27785
Pneumonol Alergol Pol 2009;77(5):469-473.

open access

Vol 77, No 5 (2009)
Submitted: 2013-02-22
Published online: 2009-08-12


In this review we presented a relation between cigarette smoking and lung cancer. We characterized molecular alterations resulting from carcinogens present in the cigarette smoke and presented the constitutive genetic profiles related to the increased risk of lung cancer. We also discussed a possible use of these profiles in the selection of high risk groups among the heavy smokers. Finally, a positive impact of quitting smoking in lung cancer patients, including those who have undergone curative resection, was presented.


In this review we presented a relation between cigarette smoking and lung cancer. We characterized molecular alterations resulting from carcinogens present in the cigarette smoke and presented the constitutive genetic profiles related to the increased risk of lung cancer. We also discussed a possible use of these profiles in the selection of high risk groups among the heavy smokers. Finally, a positive impact of quitting smoking in lung cancer patients, including those who have undergone curative resection, was presented.
Get Citation


cigarette smoking; lung cancer; gene polymorphism; risk of lung cancer; screening

About this article

Smoking and lung cancer


Advances in Respiratory Medicine


Vol 77, No 5 (2009)

Article type

Invited review paper



Published online


Page views


Article views/downloads




Bibliographic record

Pneumonol Alergol Pol 2009;77(5):469-473.


cigarette smoking
lung cancer
gene polymorphism
risk of lung cancer


Ewa Jassem
Amelia Szymanowska
Alicja Siemińska
Jacek Jassem

References (63)
  1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA: A Cancer Journal for Clinicians. 2007; 57(1): 43–66.
  2. Didkowska J, Manczuk M, McNeill A, et al. Lung cancer mortality at ages 35-54 in the European Union: ecological study of evolving tobacco epidemics. BMJ. 2005; 331(7510): 189–191.
  3. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J. 1976; 2(6051): 1525–1536.
  4. Higgins IT. Epidemiology of lung cancer in the United States. IARC Sci Publ. 1977; 16: 191–203.
  5. Little JB, Kennedy AR, McGandy RB. Lung cancer induced in hamsters by low doses of alpha radiation from polonium-210. Science. 1975; 188(4189): 737–738.
  6. Kushinsky R, Louis CJ. The effect of cigarette smoke on aryl hydrocarbon hydroxylase activity and cytochrome P450 content in rat liver and lung microsomes. Oncology. 1976; 33(5-6): 197–200.
  7. West R, Zatonski W, Przewozniak K, et al. Can we trust national smoking prevalence figures? Discrepancies between biochemically assessed and self-reported smoking rates in three countries. Cancer Epidemiol Biomarkers Prev. 2007; 16(4): 820–822.
  8. Gray N, Boyle P, Zatonski W. Tar concentrations in cigarettes and carcinogen content. Lancet. 1998; 352(9130): 787–788.
  9. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003; 3(10): 733–744.
  10. Wogan GN, Hecht SS, Felton JS, et al. Environmental and chemical carcinogenesis. Semin Cancer Biol. 2004; 14(6): 473–486.
  11. Dennisenko MF, Pao A, Tang M, et al. Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hot spots on P53. Science. 1996; 274: 430–432.
  12. Hirsch F, Fischer J, Niklinski J, et al. Future developments in the treatment of lung cancer. Lung Cancer. 2002; 38: 81–85.
  13. Jassem J, Jassem E, Jakóbkiewicz-Banecka J, et al. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Cancer. 2004; 100(9): 1951–1960.
  14. Agapitos E, Mollo F, Tomatis L, et al. Epithelial, possibly precancerous, lesions of the lung in relation to smoking, passive smoking, and socio-demographic variables. Scand J Soc Med. 1996; 24(4): 259–263.
  15. Wistuba II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 1999; 18(3): 643–650.
  16. Ogiwara H, Kohno T, Nakanishi H, et al. Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer. Oncogene. 2008; 27(35): 4788–4797.
  17. Soria JC, Xu X, Liu DD, et al. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst. 2003; 95(2): 165–168.
  18. Capkova L, Kalinova M, Krskova L, et al. Loss of heterozygosity and human telomerase reverse transcriptase (hTERT) expression in bronchial mucosa of heavy smokers. Cancer. 2007; 109(11): 2299–2307.
  19. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol. 1998; 16(3): 1207–1217.
  20. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54(18): 4855–4878.
  21. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001; 92(6): 1525–1530.
  22. Blons H, Pallier K, Le Corre D, et al. Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med Genomics. 2008; 1: 25–38.
  23. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998; 95(20): 11891–11896.
  24. Zöchbauer-Müller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001; 61(1): 249–255.
  25. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002; 62(8): 2370–2377.
  26. Brena RM, Morrison C, Liyanarachchi S, et al. Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med. 2007; 4(3): e108.
  27. West K, Linnoila I, Brognard J, et al. Tobacco Carcinogen-Induced Cellular Transformation Increases Akt Activation In Vitro and In Vivo. Chest. 2004; 125(5): 101–102.
  28. Hope BT, Nagarkar D, Leonard S, et al. Long-term upregulation of protein kinase A and adenylate cyclase levels in human smokers. J Neurosci. 2007; 27(8): 1964–1972.
  29. Szymanowska A, Jassem E, Skrzypski M, et al. Gene expression profiles In woman with lung adenocarcinoma according to cigarette smoking history. JTO. 2008(supl. 6): A 777.
  30. Powell CA, Spira A, Derti A, et al. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol. 2003; 29(2): 157–162.
  31. Lubin JH, Caporaso NE. Cigarette smoking and lung cancer: modeling total exposure and intensity. Cancer Epidemiol Biomarkers Prev. 2006; 15(3): 517–523.
  32. Sieminska A, Buczkowski K, Jassem E, et al. Lack of association between serotonin transporter gene polymorphism 5-HTTLPR and smoking among Polish population: a case-control study. BMC Med Genet. 2008; 9: 76–84.
  33. Szymanowska A, Jassem E, Dziadziuszko R, et al. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer. 2006; 52(1): 9–14.
  34. Guo Y, Zhang X, Yang M, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006; 27(1): 110–117.
  35. Jassem J, Szymanowska A, Jassem E, et al. Arg72Pro P53 gene polymorphism: Clinical relevance and relation with P53 mutations in non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 2004; 22(14_suppl): 7158–7158.
  36. Lu C, Spitz MR, Zhao H, et al. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006; 106(2): 441–447.
  37. Skuladottir H, Autrup H, Autrup J, et al. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway. Lung Cancer. 2005; 48(2): 187–199.
  38. Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(2): 491–496.
  39. Drozdowska A, Szymanowska A, Jassem E, et al. P2-011: Occurrence and clinical significance of hOGG1 Ser326Cys polymorphism in NSCLC patients from Northern Poland. Journal of Thoracic Oncology. 2007; 2(8): S486.
  40. Wu X, Zhao H, Wei Q, et al. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis. 2003; 24(3): 505–509.
  41. Zienolddiny S, Campa D, Lind H, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Mutat Res. 2004; 546: 65.
  42. Rudd MF, Webb EL, Matakidou A, et al. GELCAPS Consortium. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res. 2006; 16(6): 693–701.
  43. Wong LS, Green HM, Feugate JoE, et al. Effects of "second-hand" smoke on structure and function of fibroblasts, cells that are critical for tissue repair and remodeling. BMC Cell Biol. 2004; 5: 13.
  44. Nyberg F, Agudo A, Boffetta P, et al. A European validation study of smoking and environmental tobacco smoke exposure in nonsmoking lung cancer cases and controls. Cancer Causes Control. 1998; 9(2): 173–182.
  45. Kirkland L. Environmental Tobacco Smoke and Lung Cancer in Nonsmoking Women. JAMA: The Journal of the American Medical Association. 1995; 273(7): 519–520.
  46. Divine KK, Pulling LC, Marron-Terada PG, et al. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer. 2005; 114(3): 400–405.
  47. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst. 1993; 85(6): 457–464.
  48. Sobue T, Suzuki T, Fujimoto I, et al. Lung cancer risk among exsmokers. Jpn J Cancer Res. 1991; 82(3): 273–279.
  49. Lee IM, Cok NR, Zaziano JM, et al. Vitamin E in the primary prevention of cardiovascular and cancer: the Women’s Heath Study; a randomized controlled trial. JAMA. 2005; 294: 56–65.
  50. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996; 334(18): 1150–1155.
  51. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst. 2000; 92(12): 977–986.
  52. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988; 296(6618): 313–316.
  53. Pendyala L, Schwartz G, Bolanowska-Higdon W, et al. Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity. Cancer Epidemiol Biomarkers Prev. 2001; 10(3): 269–272.
  54. Bach PB, Kelley MJ, Tate RC, et al. Screening for lung cancer: a review of the current literature. Chest. 2003; 123(1 Suppl): 72S–82S.
  55. Hunt I, Siva M, Southon R, et al. Does lung cancer screening with low-dose computerised tomography (LDCT) improve disease-free survival? Interact Cardiovasc Thorac Surg. 2006; 5(5): 612–615.
  56. Black C, Bagust A, Boland A, et al. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess. 2006; 10(3): 1–90.
  57. Zhong Li, Hidalgo GE, Stromberg AJ, et al. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med. 2005; 172(10): 1308–1314.
  58. Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med. 2005; 171(11): 1286–1291.
  59. McRonald FE, Yadegarfar G, Baldwin DR, et al. The Liverpool Lung Project: a molecular epidemiological study of early lung cancer detection. Eur Respir J. 2002; 20(2): 464–479.
  60. Friedman GD, Flick ED, Udaltsova N, et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008; 17(1): 27–36.
  61. Jassem J. Nowotwory płuc i opłucnej. In: Szczeklik A. ed. Choroby wewnętrzne. Medycyna Praktyczna, Kraków 2005: 603–615.
  62. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med. 1993; 119(5): 383–390.
  63. Gritz ER, Nisenbaum R, Elashoff RE, et al. Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer. Cancer Causes Control. 1991; 2(2): 105–112.


Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: